Latest News Allergan Announces Leadership Changes Within its Eyecare Group, as Jag Dosanjh Takes on New Senior Position By Staff Thursday, January 20, 2022 12:24 AM Jag Dosanjh. NORTH CHICAGO, Ill.—Allergan, an AbbVie (NYSE: ABBV) company, announced this week a series of executive changes within the leadership of its eyecare group that the company said will “continue to bolster its long-standing service and commitment to the eyecare community, [and] which will position Allergan for continued innovation to help address unmet patient need.” Among the changes, Allergan said that Jag Dosanjh, formerly senior vice president, medical therapeutics, has been appointed to a newly created role of president, U.S. Neuroscience and Eyecare. Ramin Valian.As part of this new role, Dosanjh will continue to oversee the company’s commitment to advancing vision care and creating opportunities to expand its leading portfolio of treatments for eyecare providers and their patients. In addition, Ramin Valian, formerly vice president, glaucoma and reimbursement, has been named vice president, eyecare, and will oversee dry eye/refractive, glaucoma, retina, and OTC portfolios. Valian has nearly two decades of experience in the eyecare sector, and in 2021, he was honored with the Catalyst Award from the Glaucoma Research Foundation, recognizing his many contributions to ophthalmology. Glen Curran.Valian will continue the company’s focus on identifying new treatments that address unmet needs and new approaches to improve access to our products. Glen Curran, formerly vice president, anterior segment, will now serve as vice president, Botox (onabotulinumtoxinA) Therapeutic. Most recently, Curran oversaw the launch of Vuity (pilocarpine HCl ophthalmic solution) 1.25%, the latest addition to the company’s eyecare portfolio, after an earlier than expected FDA approval (in the area of presbyopia). With these changes, some responsibilities also have changed. They include: Valian will now oversee all of eyecare, including the new Vuity brand, while Curran will transition to his new role in Botox Therapeutic, a spokeswoman told VMAIL on Wednesday. Allergan noted that it looks forward to advancing its joint mission of preserving and protecting patients’ vision in partnership with eyecare professionals. Allergan has discovered, developed, and delivered more than 125 eyecare products over the last 70 years, the announcement noted.